Japanese Government Procurement

National University Corporation - Notice of Procurement (Goods & Services)Selexipag0.4mg 30tablets/case about 220cases,and 85 other contracts

This procurement is covered by the WTO Agreement on Government Procurement, Japan-EU Economic Partnership Agreement or Japan-UK Comprehensive Economic Partnership Agreement.

Japanese

Publishing date Apr 16, 2025
Type of notice Notice of Procurement (Goods & Services)
Procurement entity National University Corporation - Ibaraki
Classification
0004 Medical & Pharmaceutical Products
Summay of notice ⑴ Official in charge of disbursement of the procuring entity : Yuji Hiramatsu, The Obligating Officer Director, University of Tsukuba Hospital
⑵ Classification of the products to be procured : 4
⑶ Nature and quantity of the products to be purchased :
A Selexipag0.4mg 30tablets/case about 220cases
B Atovaquone750mg/5mL 14packs/case about 720cases
C Letermovir240mg 14tablets/case about 170cases
D Pomalidomide2mg 7capsules/case about 150cases
E Pomalidomide3mg 7capsules/case about 50cases
F Pomalidomide4mg 7capsules/case about 70cases
G Lenalidomide Hydrate 5mg 40capsules/case about 270cases
H Aflibercept (Genetical Recombination) 40mg 1syringe/case about 990cases
I Aflibercept (Genetical Recombination) 8mg 1vial/case about 230cases
J Tocilizumab (Genetical Recombination) 200mg/10mL 1vial/case about 660cases
K Antithrombin Gamma (Genetical Recombination) 600International unit about 380cases
L Brentuximab Vedotin (Genetical Recombination) 50mg 1vial/case about 130cases
M Bevacizumab (Genetical Recombination) 400mg/16mL 1vial/case about 370cases
N Cetuximab (Genetical Recombination) 100mg/20mL 1vial/case about 965cases
O Paclitaxel100mg 1vial/case about 2300cases
P Vutrisiran Sodium25mg/0.5mL 1syringe/case about 9cases
Q Fosnetupitant Chloride Hydrochloride235mg/10mL 5vials/case about 430cases
R Tremelimumab (Genetical Recombination) 300mg/15mL 1vial/case about 10cases
S Durvalumab (Genetical Recombination) 500mg/10mL 1vial/case about 560cases
T Canakinumab (Genetical Recombination) 150mg 1vial/case about 30cases
U Polyethylene Glycol Treated Human Normal Immunoglobulin5g/50mL 1vial/case about 460cases
V Polyethylene Glycol Treated Human Normal Immunoglobulin10g/100mL 1vial/case about 655cases
W Evinacumab (Genetical Recombination) 345mg/2.3mL 1vial/case about 20cases
X Epcoritamab (Genetical Recombination) 48mg/0.8mL 1vial/case about 60cases
Y Elotuzumab (Genetical Recombination) 300mg 1vial/case about 140cases
Z Trastuzumab Deruxtecan (Genetical Recombination) 100mg 1vial/case about 265cases
AA Vedolizumab (Genetical Recombination) 300mg 1vial/case about 120cases
AB Irinotecan Hydrochloride Hydrate43mg/10mL 1vial/case about 350cases
AC Landiolol Hydrochloride 50mg 5vials/case about 790cases
AD Nivolumab (Genetical Recombination) 20mg/2mL 1vial/case about 860cases
AE Nivolumab (Genetical Recombination) 240mg/24mL 1vial/case about 1350cases
AF Abatacept (Genetical Recombination) 250mg 1vial/case about 700cases
AG Obinutuzumab (Genetical Recombination) 1000mg/40mL 1vial/case about 55cases
AH Trastuzumab Emtansine (Genetical Recombination) 100mg 1vial/case about 130cases
AI Trastuzumab Emtansine (Genetical Recombination) 160mg 1vial/case about 60cases
AJ Pembrolizumab (Genetical Recombination) 100mg/4mL 1vial/case about 1870cases
AK Freeze-dried Polyethylene Glycol Treated Human Normal Immunoglobulin
5000mg/100mL 1vial/case about 730cases
AL Ofatumumab (Genetical Recombination) 20mg/0.4mL 1kit/case about 150cases
AM Ramucirumab (Genetical Recombination) 100mg/10mL 1vial/case about 310cases
AN Ramucirumab (Genetical Recombination) 500mg/50mL 1vial/case about 105cases
AO Isatuximab (Genetical Recombination) 500mg/25mL 1vial/case about 70cases
AP Pegfilgrastim (Genetical Recombination) 3.6mg 1syringe/case about 390cases
AQ Pegfilgrastim (Genetical Recombination) 3.6mg/0.36mL 1kit/case about 380cases
AR Golimumab (Genetical Recombination) 50mg/0.5mL 1kit/case about 280cases
AS Palivizumab (Genetical Recombination) 100mg 1vial/case about 260cases
AT Ustekinumab (Genetical Recombination) 45mg/0.5mL 1syringe/case about 280cases
AU Risankizumab (Genetical Recombination) 150mg 1syringe/case about 260cases
AV Risankizumab (Genetical Recombination) 360mg/2.4mL 1kit/case about 80cases
AW Lanreotide Acetate120mg 1syringe/case about 60cases
AX Tazobactam Sodium-Piperacillin Sodium for Injection4.5g 10vials/case about 1870cases
AY Daratumumab (Genetical Recombination)・Vorhyaluronidase Alfa (Genetical Recombination) 15mL 1vial/case about 350cases
AZ Atezolizumab (Genetical Recombination) 1200mg/20mL 1vial/case about 190cases
BA Guselkumab (Genetical Recombination) 100mg 1syringe/case about 120cases
BB Mepolizumab (Genetical Recombination) 100mg 1kit/case about 150cases
BC Avalglucosidase Alfa (Genetical Recombination) 100mg 1vial/case about 380cases
BD Eptacog Alfa (Activated) (Genetical Recombination) 5mg/5.2mL 1kit/case about 80cases
BE Enfortumab Vedotin (Genetical Recombination) 20mg 1vial/case about 230cases
BF Enfortumab Vedotin (Genetical Recombination) 30mg 1vial/case about 410cases
BG Pertuzumab (Genetical Recombination) 420mg/14mL 1vial/case about 130cases
BH Eribulin Mesilate1mg/2mL 1vial/case about 260cases
BI Palonosetron Hydrochloride0.75mg/50mL 1pack/case about 810cases
BJ Avelumab (Genetical Recombination) 200mg/10mL 1vial/case about 590cases
BK Clazosentan Sodium150mg/6mL 10vials/case about 40cases
BL pH4-Treated Normal Human Immunoglobulin20g/200mL 1vial/case about 270cases
BM Efgartigimod Alfa (Genetical Recombination)・Vorhyaluronidase Alfa (Genetical Recombination) 5.6mL 1vial/case about 65cases
BN Azacitidine100mg 1vial/case about 800cases
BO Blinatumomab (Genetical Recombination) 35㎍ 1vial/case about 240cases
BP fulvestrant250mg/5mL 2syringes/case about 230cases
BQ Pertuzumab (Genetical Recombination)・Trastuzumab (Genetical Recombination)・Vorhyaluronidase Alfa (Genetical Recombination) 15mL 1vial/case about 40cases
BR Denosumab (Genetical Recombination) 60mg/1mL 1syringe/case about 650cases
BS Denosumab (Genetical Recombination) 120mg/1.7mL 1vial/case about 980cases
BT Sugammadex Sodium200mg/2mL 10vials/case about 360cases
BU Nirsevimab (Genetical Recombination) 50mg/0.5mL 1syringe/case about 90cases
BV Panitumumab (Genetical Recombination100mg/5mL 1vial/case about 325cases
BW Panitumumab (Genetical Recombination400mg/20mL 1vial/case about 90cases
BX Inotuzumab Ozogamicin (Genetical Recombination) 1mg 1vial/case about 20cases
BY Remdesivir100mg 1vial/case about 480cases
BZ Heparin Sodium10mL 10syringes/case about 10660cases
CA Bevacizumab (Genetical Recombination) [Bevacizumab Biosimilar4] 400mg/16mL 1vial/case about 1030cases
CB Lyophilized Human C1-inactivator Concentrate 500 International unit about 270cases
CC Ipilimumab (Genetical Recombination) 50mg/10mL 1vial/case about 190cases
CD Inebilizumab (Genetical Recombination) 100mg/10mL 3vials/case about 4cases
CE Rituximab (Genetical Recombination) [Rituximab Biosimilar1] 500mg/50mL 1vial/case about 470cases
CF Leuprorelin Acetate 22.5mg 1syringe/case about 310cases
CG Leuprorelin Acetate11.25mg 1syringe/case about 600cases
CH infliximab (genetical recombination)100mg 1vial/case about 1150cases
CI Romiplostim (Genetical Recombination)250㎍ 1vial/case about 1305cases
CJ Human fibrinogen, Human antihemophilic factor XIII fraction, Aprotinin Solution, Thrombin, Calcium Chloride Hydrate5mL 2kit/case about 250cases
⑷ Delivery period : From 1 July, 2025 through 31 March, 2026
⑸ Delivery place : The University of Tsukuba Hospital
⑹ Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall :
A not come under Article 46 and 47 of the Regulation concerning the Contract for University of Tsukuba Furthermore, minors, Person under Conservatorship or Person under Assistance that obtained the consent necessary for concluding a contract may be applicable under cases of special reasons within the said clause,
B have the Grade A, Grade B or Grade C qualification during fiscal 2025 in the Kanto・Koshinetsu area in sales of product for participating in tenders by Single qualification for every ministry and agency,
C prove to have obtained either the first-class license or the third-class license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices,
D prove to have the ability to deliver the products, required by this notice, on the date and to the place specified by The Obligating Officer,
E meet the qualification requirements which The Obligating Officer Director may specify in accordance with Article 49 of the Regulation,
F not be currently under a suspension of business order as instructed by The Obligating Officer.
⑺ Time limit of tender : 12 : 00 6 June, 2025
⑻ Contact point for the notice : Natsuko Kimura, Division of Accounting, Department of University Hospital Management, University of Tsukuba, 2-1-1 Amakubo Tsukuba-shi 305-8576 Japan, TEL 029-853-3586
⑼ Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.